Denver, CONCT05873686Now EnrollingIRB Ready

Advanced Solid Tumor Clinical Trial in Denver, CO

Access cutting-edge advanced solid tumor treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by Nuvectis Pharma, Inc.

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access advanced solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumor treatment provided free

Apply for This Denver Location

Check if you qualify for this advanced solid tumor clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This Advanced Solid Tumor Study in Denver

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Sponsor: Nuvectis Pharma, Inc.

Who Can Participate

Inclusion Criteria

Provide written informed consent.
18 years old or older.
Advanced, metastatic, and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies are considered inappropriate by the Investigator.
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

Exclusion Criteria

Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpressing malignancies.
Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP900. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.
Ongoing toxic manifestations of previous treatments \> Grade 2 with the exception of alopecia and neuropathy.
Subjects with treated brain metastases with evidence of progression within 28 days after central nervous system (CNS)-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\] scan) during the Screening period.
Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to use at least one highly effective form of contraception .
Male subjects with partners of childbearing potential, unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide).
Major surgery from which the subject has not yet recovered. Part B: Inclusion Criteria:
Provide written informed consent.
18 years old or older.
Advanced, metastatic, and/or progressive solid tumors with pathogenic molecular alterations:
Non-small cell lung cancer (adenocarcinoma); YES1, TYMS amplification or FAT1 pathogenic mutation
Non-small cell lung cancer (squamous cell carcinoma); YES1, TYMS amplification or FAT1 pathogenic mutation
Renal cancer; NF2 pathogenic mutation
Mesothelioma; NF2 pathogenic mutation
Other solid tumors with a NF2, FAT1 or LATS1 pathogenic gene mutation or TYMS, YAP1, YES1, or TAZ1 gene amplification, or cholangiocarcinoma with IDH1 or IDH2 mutations.
Must have received 1-3 prior therapies appropriate for their tumor type and stage of disease
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (or mRECIST 1.1 for subjects with pleural mesothelioma).
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Exclusion Criteria:
Subjects with the following combination of cancer type and pathogenic molecular alterations are excluded:
Subjects with colorectal cancer, glioma, melanoma, or anaplastic thyroid conditions with BRAF mutations.
Subjects with NSCLC with BRAF or EGFR mutations or HER2 overexpression.
Subjects with breast cancer, gastric cancer, esophageal junction adenocarcinoma or biliary cancer with HER2 alterations,
Subjects with anal, penile, cervical or head and neck cancers with a prior history of human papilloma virus (HPV) infection.
Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days (42 days for nitrosoureas, mitomycin-C) prior to first dose of NXP900. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.
Ongoing toxic manifestations of previous treatments \> Grade 2 with the exception of alopecia and neuropathy.
Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to use at least one highly effective form of contraception .
Male subjects with partners of childbearing potential, unless they agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide).
Major surgery from which the subject has not yet recovered.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT05873686) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumor Treatment Options in Denver, CO

If you're searching for advanced solid tumor treatment options in Denver, CO, this clinical trial (NCT05873686) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Denver, CO

See all advanced solid tumors clinical trials recruiting in Denver — not just this study.

Browse Advanced Solid Tumors Trials in Denver →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO